Adult Dosing
Complicated intra-abdominal infections
Complicated skin and skin structure infections
- 1 g IM/IV qd x 7-10 days
- Includes adult patients with diabetic foot infections received up to 28 days of treatment
Community acquired pneumonia
- 1 g IM/IV qd x 10-14 days
- Switch to an appropriate oral therapy, after at least 3 days of IM/IV therapy, once clinical improvement established
Complicated urinary tract infections
- 1 g IM/IV qd x 10-14 days
- Switch to an appropriate oral therapy, after at least 3 days of IM/IV therapy, once clinical improvement established
Acute pelvic infections including postpartum endomyometritis, septic abortion, and post surgical gynecologic infections
Prophylaxis of surgical site infection following elective colorectal surgery
- 1 g IV x1 ; give 1 hr prior to surgical incision
Pediatric Dosing
Complicated intra-abdominal infections
- Child 3 month-12 yrs: 30 mg/kg/day IM/IV divided bid x 5-14 days. Max: 1 g/day
- > 13 yrs: 1 g IM/IV qd x 5-14 days
Complicated skin and skin structure infections
- Child 3 month-12 yrs: 30 mg/kg/day IM/IV divided bid x 1-2 wks. Max: 1 g/day
- > 13 yrs: 1 g IM/IV qd x 7-14 days
Community acquired pneumonia
- Child 3 month-12 yrs: 30 mg/kg/day IM/IV divided bid x 10-14 days. Max: 1 g/day
- > 13 yrs: 1 g IM/IV qd x 10-14 days
Complicated urinary tract infections
- Child 3 month-12 yrs: 30 mg/kg/day IM/IV divided bid x 10-14 days. Max: 1 g/day
- > 13 yrs: 1 g IM/IV qd x 10-14 days
Acute pelvic infections including postpartum endomyometritis, septic abortion, and post surgical gynecologic infections
- Child 3 month-12 yrs: 30 mg/kg/day IM/IV divided bid x 3-10 days. Max: 1 g/day
- > 13 yrs: 1 g IM/IV qd x 3-10 days
Renal Dose Adjustment (Based on CrCl)
30 mL/min: 500 mg qd- Hemodialysis: Administer 150 mg supplement only if maintenance dose given <6 hrs prior to HD
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on beta-lactam therapy. This is more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens
- Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been reported to occur over two months after the administration of antibacterial agents
- Treatment with epinephrine and other emergency measures required in serious acute hypersensitivity reactions
- Drug should be discontinued if allergic reaction occurs
- Therapy may cause seizures and other CNS adverse reactions. Anticonvulsant therapy should be continued in patients with known seizure disorders
- Avoid prescribing in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication as it may increase the risk of the development of drug-resistant bacteria
- Caution advised when administering intramuscularly to avoid inadvertent injection into a blood vessel
Cautions: Use cautiously in
- Renal impairment
- History of seizure
- CNS disorder
- Hypersensitivity to beta-lactams
- Hypersensitivity to multiple allergens
Pregnancy Category:B
Breastfeeding: Safe. Limited information indicates that single maternal doses of ertapenem up to 1 gram produce low levels in milk that are not expected to cause adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 9 March 2011). Manufacturer advises caution.
